Oscotec’s FDA-approved clinical trials for treatment of acute myeloid leukemia
Oscotec(CEO Jung-Geun Kim), a new drug development company, announced on the 13th that it made an agreement since the U.S. Phase 1 clinical trial project of the next-generation new drug candidate(SKI-G-801) for the treatment of acute myeloid leukemia(AML) was selected as the non-clinical/clinical...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.